Revenue
No reported data
Oric Pharmaceuticals, Inc. (ORIC)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Research & development | $109.8M | $114.1M | $85.2M | $61.7M | $56.9M | $35.9M | $22.8M | $19.0M |
| Operating expenses | $143.0M | $142.9M | $110.8M | $91.8M | $78.9M | $74.2M | $28.6M | $22.4M |
| Operating income | −$143.0M | −$142.9M | −$110.8M | −$91.8M | −$78.9M | −$74.2M | −$28.6M | −$22.4M |
| Net income | −$129.5M | −$127.8M | −$100.7M | −$89.1M | −$78.7M | −$73.7M | −$26.9M | −$21.4M |
| Basic EPSper diluted share | -$1.47 | -$1.83 | -$1.96 | -$2.25 | -$2.07 | -$3.36 | -$14.15 | -$12.32 |
| Diluted EPSper diluted share | -$1.47 | -$1.83 | -$1.96 | -$2.25 | -$2.07 | -$3.36 | -$14.15 | -$12.32 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 24, 2026Form 4 · 10b5-1 | Piscitelli DominicChief Financial Officer | SellCommon Stock | 52.0K | $13.51 | $702.5K | 68.1K |
| Jan 16, 2026Form 4 · 10b5-1 | Heyman Richard A.Director | SellCommon Stock · indirect | 3.2K | $12.00 | $38.4K | 213.1K |
| Jan 16, 2026Form 4 · 10b5-1 | Heyman Richard A.Director | SellCommon Stock | 3.5K | $12.00 | $42.0K | 41.8K |
| Dec 16, 2025Form 4 | Piscitelli DominicChief Financial Officer | SellCommon Stock | 10.7K | $9.06 | $97.1K | 68.1K |
| Dec 16, 2025Form 4 | Chacko JacobPRESIDENT AND CEO | SellCommon Stock | 33.4K | $9.06 | $302.4K | 581.7K |